✦ LIBER ✦

Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppressive chemotherapy

✍ Scribed by Wayne L. Furman; John H. Rodman; Margaret E. Tonda; Xiaolong Luo; Bettye Arnold; Neyssa Marina; Leslie Garrison; Roberta Hanna; Charles B. Pratt; William H. Meyer

Publisher: Springer
Year: 1997
Tongue: English
Weight: 219 KB
Volume: 41
Category: Article
ISSN: 0344-5704
DOI: 10.1007/s002800050733

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics of intravenous recombin

Pharmacokinetics of intravenous recombinant human granulocyte colony-stimulating factor (rhG-CSF) in children receiving myelosuppressive cancer chemotherapy: Clearance increases in relation to absolute neutrophil count with repeated dosing

✍ Sturgill, Marc G.; Huhn, Richard D.; Drachtman, Richard A.; Ettinger, Alice G.; 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 2 views

Limited evidence suggests increased efficacy of rhG-CSF by subcutaneous (SQ) compared with intravenous (IV) administration. To examine the possibility that rapid elimination of IV rhG-CSF could substantially shorten the duration of systemic exposure and could explain a difference in pharmacodynamics

Expression of Bcl-2 and p53 protein in r

Expression of Bcl-2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: Effects on clinical outcome and efficacy of adjuvant chemotherapy

✍ Yoshinori Nio; Ming Dong; Chikage Iguchi; Kunihiro Yamasawa; Tomoko Toga; Masayu 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB

## Abstract ## Background and Objectives p53 tumor suppressor gene has a dual role as a trigger of apoptosis and as an initiator of DNA repair. The Bcl‐2 can work to protect cells from apoptosis, which is induced by p53 gene. These facts suggest the significant role of these genes in the genesis a